Logo
x

Search

Subscribe Now

Basilea

Basilea Announces the US FDA Approval of Cresemba (isavuconazole) in Pediatric Patients to Treat Invasive Aspergillosis & Invasive Mucormycosis

Basilea Announces the US FDA Approval of Cresemba (isavuconazole) in Pediatric Patients to Treat Invasive Aspergillosis & Invasive...

  • December 11, 2023
Basilea Published P-III Study (ERADICATE) Results of Ceftobiprole for Staphylococcus Aureus Bacteremia in the NEJM

Basilea Published P-III Study (ERADICATE) Results of Ceftobiprole for Staphylococcus Aureus Bacteremia in the NEJM

  • September 28, 2023
Basilea Reports the NDA Submission of Ceftobiprole for the Treatment of Severe Bacterial and Fungal Infections

Basilea Reports the NDA Submission of Ceftobiprole for the Treatment of Severe Bacterial and Fungal Infections

  • August 4, 2023
Basilea Entered into an Asset Purchase and Sub-License Agreement with SillaJen for BAL0891

Basilea Entered into an Asset Purchase and Sub-License Agreement with SillaJen for BAL0891

  • September 20, 2022
Basilea Reports Results of Ceftobiprole in the P-III (ERADICATE) Study for the Treatment of Staphylococcus Aureus Bacteremia

Basilea Reports Results of Ceftobiprole in the P-III (ERADICATE) Study for the Treatment of Staphylococcus Aureus Bacteremia

  • June 28, 2022
Basilea and Pfizer Collaborated to Commercialize Cresemba for Invasive Aspergillosis and Mucormycosis

Basilea and Pfizer Collaborated to Commercialize Cresemba for Invasive Aspergillosis and Mucormycosis

  • June 17, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.